People | February 22, 2022
Biosion appoints Joel Edwards as Chief Business Officer
Prior to joining Biosion, Edwards was Vice President of Corporate Strategy and operations at Ionis Pharmaceuticals.
Prior to joining Biosion, Edwards was Vice President of Corporate Strategy and operations at Ionis Pharmaceuticals.
The researchers are of the view that the new drug designing strategy demonstrated by them could also be adopted to treat retroviral infections.
The focus should be on streamlining regulations, developing new molecules, increased industry academia collaboration and tapping the potential of traditional medicines
AROC3-1001 is a phase 1/2, placebo controlled, dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-C3
Ligand expects 2022 royalties of $55 million to $60 million, material sales of $40 million to $50 million, and contract revenue of $52 million to $62 million.
Funding will support continued advancement of Centauri’s antimicrobial resistance research to identify novel therapeutic candidates using its proprietary Alphamer platform
Dr. Peter Houghton will lead the research collaboration for GCCRI and is widely regarded as a leading expert in pediatric cancer research and in the development of novel approaches to treating childhood cancers
_256_384.jpg){kind=logo}
Shilpa Biologicals has tie-ups with Zydus to supply ZyCoV-D vaccine drug substance and Dr Reddy’s to make Sputnik V from its facility in Dharwad
GOSTAR's proprietary data set underwent rigorous analysis and large-scale ML model building to predict drug solubility in a recent joint study. X-Chem's RosalindAI delivered superior and actionable results than other similar analyses using well-known publically available datasets
Senior R&D leader from Pfizer and bluebird bio to support Strand’s platform of programmable mRNA-based therapeutics
Subscribe To Our Newsletter & Stay Updated
